Needham & Company LLC Cuts Collegium Pharmaceutical (NASDAQ:COLL) Price Target to $46.00

Collegium Pharmaceutical (NASDAQ:COLL) had its price objective lowered by research analysts at Needham & Company LLC from $56.00 to $46.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective would indicate a potential upside of 58.59% from the company’s current price.

A number of other analysts have also weighed in on COLL. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 25th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $55.00.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL traded down $6.74 during trading hours on Thursday, reaching $29.00. 1,366,140 shares of the stock traded hands, compared to its average volume of 474,402. The company’s 50-day simple moving average is $34.95 and its two-hundred day simple moving average is $37.24. The company has a market capitalization of $940.75 million, a P/E ratio of 14.28 and a beta of 0.73. Collegium Pharmaceutical has a 52-week low of $29.21 and a 52-week high of $50.79. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm had revenue of $199.88 million for the quarter, compared to the consensus estimate of $199.62 million. During the same period last year, the firm posted $1.68 earnings per share. The business’s revenue was up 6.3% compared to the same quarter last year. Equities research analysts forecast that Collegium Pharmaceutical will post 6.76 EPS for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of large investors have recently added to or reduced their stakes in COLL. Janus Henderson Group PLC increased its position in shares of Collegium Pharmaceutical by 59.1% during the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock valued at $67,026,000 after purchasing an additional 538,337 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Collegium Pharmaceutical by 65.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after buying an additional 518,721 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after acquiring an additional 461,914 shares during the last quarter. Two Sigma Investments LP grew its position in shares of Collegium Pharmaceutical by 897.2% during the 3rd quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock valued at $9,423,000 after acquiring an additional 242,310 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Collegium Pharmaceutical in the 2nd quarter worth $8,506,000.

More Collegium Pharmaceutical News

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Q2 adjusted earnings exceeded expectations. Collegium reported adjusted EPS of $1.92, ahead of the $1.72 consensus estimate and up from $1.68 a year earlier. Revenue of $199.9 million also modestly surpassed estimates and increased approximately 6% year over year. Collegium Pharmaceutical Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: ADHD growth and the AZSTARYS acquisition support the long-term outlook. JORNAY PM revenue rose 41% to $46.1 million, while AZSTARYS contributed $12.9 million during its partial quarter following the completed acquisition. Collegium raised its 2026 AZSTARYS revenue outlook to $65 million–$75 million from $60 million–$70 million. Collegium Reports Q2 Results and Completes AZSTARYS Acquisition
• Positive Sentiment: Operating cash flow was strong at $71.3 million, and adjusted EBITDA increased 8% year over year to $113.8 million, providing financial support for integration and future investment.
• Neutral Sentiment: The company reaffirmed its JORNAY PM revenue forecast of $190 million–$200 million, indicating continued confidence in its established ADHD product.
• Negative Sentiment: Full-year guidance was cut below Wall Street expectations. Collegium now expects 2026 product revenue of $825 million–$855 million, down from $865 million–$895 million and below the approximately $872.4 million consensus estimate. Adjusted EBITDA guidance was also reduced to $445 million–$470 million from $475 million–$500 million.
• Negative Sentiment: The pain portfolio remains under pressure. Pain revenue declined 9% year over year to $140.9 million, led by a 24% drop in Nucynta franchise revenue and a 14% decrease in Xtampza ER revenue. Management attributed the guidance reduction largely to lower-than-expected pricing for Nucynta authorized generics.
• Negative Sentiment: GAAP results deteriorated to a $15.1 million net loss from $12.0 million of net income a year earlier, while GAAP operating expenses increased 45%, partly reflecting acquisition-related costs and higher amortization.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.